|
1
|
De Gramont A, Figer A, Seymour M, Homerin
M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer
G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F,
Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with
or without oxaliplatin as first-line treatment in advanced
colorectal cancer. J Clin Oncol. 18:2938–2947. 2000.
|
|
2
|
Benoist S, Brouquet A, Penna C, Julié C,
El Hajjam M, Chagnon S, Mitry E, Rougier P and Nordlinger B:
Complete response of colorectal liver metastases after
chemotherapy: does it mean cure? J Clin Oncol. 24:3939–3945. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kato T, Shimamoto Y, Uchida J, Ohshimo H,
Abe M, Shirasaka T and Fukushima M: Possible regulation of
5-fluorouracil-induced neuro- and oral toxicities by two
biochemical modulators consisting of S-1, a new oral formulation of
5-fluorouracil. Anticancer Res. 21:1705–1712. 2001.PubMed/NCBI
|
|
4
|
Yamada Y, Tahara M, Miya T, Satoh T,
Shirao K, Shimada Y, Ohtsu A, Sasaki Y and Tanigawara Y: Phase I/II
study of oxaliplatin with oral S-1 as first-line therapy for
patients with metastatic colorectal cancer. Br J Cancer.
98:1034–1038. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ohtsu A, Baba H, Sakata Y, Mitachi Y,
Horikoshi N, Sugimachi K and Taguchi T: Phase II study of S-1, a
novel oral fluoropyrimidine derivative, in patients with metastatic
colorectal carcinoma. Br J Cancer. 83:141–145. 2000.PubMed/NCBI
|
|
6
|
Shirao K, Ohtsu A, Takada H, Mitachi Y,
Hirakawa K, Horikoshi N, Okamura T, Hirata K, Saitoh S, Isomoto H
and Satoh A: Phase II study of oral S-1 for treatment of metastatic
colorectal carcinoma. Cancer. 100:2355–2361. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang J, Chung K, Zergebel C, Urrea P,
Quinones M and Saltz L: Phase I study of oral S-1 in combination
with oxaliplatin (oxali) and bevacizumab (bev) in patients with
advanced solid tumors. J Clin Oncol ASCO Annual Meeting Proceedings
Part I. 25(Suppl): 40912007.
|
|
8
|
Couinaud C: Le foie Etudes anatomiques et
chirurgicales. Masson; Paris: 1957
|
|
9
|
Beckurts KT, Holscher AH, Thorban S,
Bollschweiler E and Siewert JR: Significance of lymph node
involvement at the hepatic hilum in the resection of colorectal
liver metastases. Br J Surg. 84:1081–1084. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hananel N, Garzon J and Gordon PH: Hepatic
resection for colorectal liver metastases. Am Surg. 61:444–447.
1995.PubMed/NCBI
|
|
11
|
Scheele J, Stang R, Altendorf-Hofmann A
and Paul M: Resection of colorectal liver metastases. World J Surg.
19:59–71. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shimizu Y, Yasui K, Sano T, Hirai T,
Kanemitsu Y, Komori K and Kato T: Treatment strategy for
synchronous metastases of colorectal cancer: is hepatic resection
after an observation interval appropriate? Langenbecks Arch Surg.
392:535–538. 2007. View Article : Google Scholar
|
|
13
|
Shimizu Y, Yasui K, Sano T, Hirai T,
Kanemitsu Y, Komori K and Kato T: Validity of observation interval
for synchronous hepatic metastases of colorectal cancer: changes in
hepatic and extrahepatic metastatic foci. Langenbecks Arch Surg.
393:181–184. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wood CB, Gillis CR and Blumgart LH: A
retrospective study of the natural history of patients with liver
metastases from colorectal cancer. Clin Oncol. 2:285–288.
1976.PubMed/NCBI
|
|
15
|
Wagner JS, Adson MA, Van Heerden JA, Adson
MH and Ilstrup DM: The natural history of hepatic metastases from
colorectal cancer: A comparison with respective treatment. Ann
Surg. 199:502–508. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saltz LB, Cox JV, Blanke C, Rosen LS,
Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta
N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and
leucovorin for metastatic colorectal cancer: Irinotecan Study
Group. N Engl J Med. 343:905–914. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
LiverMetSurvey. International registry of
liver metastases of colorectal cancer. http://www.livermetsurvey.org.
|
|
18
|
Choti MA, Sitzmann JV, Tiburi MF,
Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ and
Cameron JL: Trends in long-term survival following liver resection
for hepatic colorectal metastases. Ann Surg. 235:759–766. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Abdalla EK, Vauthey JN, Ellis LM, Ellis V,
Pollock R, Broglio KR, Hess K and Curley SA: Recurrence and
outcomes following hepatic resection, radiofrequency ablation, and
combined resection/ablation for colorectal liver metastases. Ann
Surg. 239:818–825. 2004. View Article : Google Scholar
|
|
20
|
Adam R, Wicherts DA, de Haas RJ, Aloia T,
Lévi F, Paule B, Guettier C, Kunstlinger F, Delvart V, Azoulay D
and Castaing D: Complete pathologic response after preoperative
chemotherapy for colorectal liver metastases: myth or reality? J
Clin Oncol. 26:1635–1641. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Blazer DG III, Kishi Y, Maru DM, Kopetz S,
Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D,
Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK and
Vauthey JN: Pathologic response to preoperative chemotherapy: a new
outcome end point after resection of hepatic colorectal metastases.
J Clin Oncol. 26:5344–5351. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Adam R, Wicherts DA, de Haas RJ, Ciacio O,
Lévi F, Paule B, Ducreux M, Azoulay D, Bismuth H and Castaing D:
Patients with initially unresectable colorectal liver metastases:
is there a possibility of cure? J Clin Oncol. 27:1829–1835. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ribero D, Wang H, Donadon M, Zorzi D,
Thomas MB, Eng C, Chang DZ, Curley SA, Abdalla EK, Ellis LM and
Vauthey JN: Bevacizumab improves pathologic response and protects
against hepatic injury in patients treated with oxaliplatin-based
chemotherapy for colorectal liver metastases. Cancer.
110:2761–2767. 2007. View Article : Google Scholar
|
|
24
|
Okines A, Puerto OD, Cunningham D, Chau I,
Van Cutsem E, Saltz L and Cassidy J: Surgery with curative-intent
in patients treated with first-line chemotherapy plus bevacizumab
for metastatic colorectal cancer First BEAT and the randomised
phase-III NO16966 trial. Br J Cancer. 101:1033–1038. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kishi Y, Zorzi D, Contreras CM, Maru DM,
Kopetz S, Ribero D, Motta M, Ravarino N, Risio M, Curley SA,
Abdalla EK, Capussotti L and Vauthey JN: Extended preoperative
chemotherapy does not improve pathologic response and increases
postoperative liver insufficiency after hepatic resection for
colorectal liver metastases. Ann Surg Oncol. June 22–2010.(Epub
ahead of print).
|
|
26
|
Karoui M, Penna C, Amin-Hashem M, Mitry E,
Benoist S, Franc B, Rougier P and Nordlinger B: Influence of
preoperative chemotherapy on the risk of major hepatectomy for
colorectal liver metastases. Ann Surg. 243:1–7. 2006. View Article : Google Scholar
|
|
27
|
Aloia T, Sebagh M, Plasse M, Karam V, Lévi
F, Giacchetti S, Azoulay D, Bismuth H, Castaing D and Adam R: Liver
histology and surgical outcomes after preoperative chemotherapy
with fluorouracil plus oxaliplatin in colorectal cancer liver
metastases. J Clin Oncol. 24:4983–4990. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rubbia-Brandt L, Lauwers GY, Wang H, Majno
PE, Tanabe K, Zhu AX, Brezault C, Soubrane O, Abdalla EK, Vauthey
JN, Mentha G and Terris B: Sinusoidal obstruction syndrome and
nodular regenerative hyperplasia are frequent
oxaliplatin-associated liver lesions and partially prevented by
bevacizumab in patients with hepatic colorectal metastasis.
Histopathology. 56:430–439. 2010. View Article : Google Scholar
|
